NCT03375255View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

August 19, 2019

Study Completion Date

August 19, 2019

Conditions

Muscular Dystrophy, Duchenne

Interventions

DRUG

SRP-5051

Single dose of SRP-5051 administered as an intravenous (IV) infusion.

Trial Locations (8)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

30318

Rare Disease Research, LLC, Atlanta

32561

NW FL Clinical Research Group, LLC, Gulf Breeze

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

66160

University of Kansas Medical Center, Kansas City

75207

Children's Medical Center Dallas, Dallas

95817

Neuromuscular Research Center, Sacramento

N6A 5W9

London Health Sciences Centre, London

All Listed Sponsors

lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT03375255 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter